Rapid Development of CHO Cell Lines for High-Level Production of Recombinant Antibodies

by Daniel S. Allison, PhD, Michael Brandenstein, Lynn Davis, Jennifer Running Deer, Nilesh Shah, PhD, and Kristin Ziegler
Volume 2, Issue 2 (March/April 2003)

Organizations developing biopharmaceuticals are often faced with the challenge of developing, as rapidly as possible, a production system for a recombinant protein or antibody intended for use in clinical trials. For expression of antibodies and other proteins with complex post-translational modifications, Chinese hamster ovary (CHO) cells are often the host of choice. However, isolation of CHO cell lines producing even moderate levels of a protein of interest is usually a lengthy process due to the need for at least one and usually several gene amplification steps. Gene amplification, which is usually accomplished through the dihydrofolate reductase (dhfr)/methotrexate system, is a requirement for most CHO expression vectors because the absolute expression level from each copy of an integrated expression plasmid is generally very low...

Citation:
Allison DS, Brandenstein M, Davis L, Running Deer J, Shah N, Ziegler K. Rapid Development of CHO Cell Lines for High-Level Production of Recombinant Antibodies. BioProcess J, 2003; 2(2): 33-40. http://dx.doi.org/10.12665/J22.Allison.